Cleared Traditional

K172033 - Pirouette High Pressure (HP) (FDA 510(k) Clearance)

Class II Cardiovascular device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K172033 · Arravasc, Ltd. · Cardiovascular device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 2017
Decision
57d
Days
Class 2
Risk

K172033 is an FDA 510(k) clearance for the Pirouette High Pressure (HP). Classified as Catheter, Angioplasty, Peripheral, Transluminal (product code LIT), Class II - Special Controls.

Submitted by Arravasc, Ltd. (Galway, IE). The FDA issued a Cleared decision on August 31, 2017 after a review of 57 days - a notably fast clearance cycle.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.1250 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Arravasc, Ltd. devices

Submission Details

510(k) Number K172033 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 05, 2017
Decision Date August 31, 2017
Days to Decision 57 days
Submission Type Traditional
Review Panel Cardiovascular (CV)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
68d faster than avg
Panel avg: 125d · This submission: 57d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code LIT Catheter, Angioplasty, Peripheral, Transluminal
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 870.1250
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Cardiovascular devices follow this clearance model.

Regulatory Peers - LIT Catheter, Angioplasty, Peripheral, Transluminal

All 401
Devices cleared under the same product code (LIT) and FDA review panel - the closest regulatory comparables to K172033.
Armada™ 14 NC PTA Catheter
K252512 · Abbott Medical · Feb 2026
Amethyst HP PTA OTW 0.035 Catheter
K251915 · Natec Medical , Ltd. · Dec 2025
Passeo-35 Xeo Peripheral Dilatation Catheter
K250706 · Biotronik, Inc. · Apr 2025
Parafleet SC 014 PTA Balloon Dilatation Catheter
K243704 · Brosmed Medical Co., Ltd. · Feb 2025
Amethyst HP PTA OTW 0.035 Catheter
K241040 · Natec Medical , Ltd. · Dec 2024
018 Hydrophilic Coated OTW PTA Balloon Dilatation Catheter
K242419 · Creagh Medical Ltd. Dba Surmodics, Inc. · Nov 2024